Cogstate

In Schizophrenia clinical trials, improvement in cognition is often seen in both the treatment and placebo groups. Cogstate Senior Scientist, Dr. Svenja Wacker, recently presented data at #ISCTM evaluating whether placebo response or practice effects could be contributing factors. Data gathered from a clinical trial of adults with chronic Schizophrenia showed that no practice effects were observed across a battery of Cogstate digital tests, even when tests were repeated at short intervals. Watch this poster summary to see the data and learn more: https://lnkd.in/eyrZBPXq

The Groton Maze Learning Test (GMLT) is a powerful tool to assess the problem-solving and reasoning aspects of executive function 🧠. The GMLT is digital, non-verbal, and highly sensitive to the effects of disease and drugs in both clinical application and clinical trial contexts. This Cogstate-version of a standardized maze-learning cognitive paradigm is used across all phases of trials, notably in several late-phase schizophrenia programs such as the PEARL-3 lurasidone studies and novel CAR T-cell oncology research. 🌟 More details on how the GMLT assesses cognition, and the many other digital cognitive assessments offered on the Cogstate platform- https://lnkd.in/e53Wt6tC #Cognition #BrainHealthForAll #Neuroscience

Recently Cogstate CSO, Dr. Pam Ventola, was asked to describe ways to mitigate placebo response in rare disease trials. She answers the query in this brief video, describing the significance of comprehensive education for both site staff and caregivers with an approach of integrating objective outcomes and placebo response training to enhance the reliability of trial results > https://lnkd.in/d2pxdemF

If using digital, non-invasive tests in a matter of minutes to detect cognitive decline sounds simple—that’s because it is (and that’s the goal). Cogstate was founded to democratise brain health and make it easier for physicians and patients to detect decline earlier, and track it over time. With therapeutics in the mix, getting the diagnostic process started early is paramount for solutions to be most effective. I’m proud of my colleagues for their determination to ensure #BrainHealthforAll. Thanks to Davos Alzheimer's Collaborative for including me and noting Cogstate’s cognitive tests in this series. We’re on the precipice of major change in the industry. By transforming the patient journey through low-cost tools that free up physicians’ time, we’ll ease the diagnostic process—making sure more people get the care they need. https://lnkd.in/gFYcHAgX

Developing a framework to decide whether to continue or stop your drug development efforts in Alzheimer’s disease is vital to avoid wasting time and resources on an ineffective drug. Here we summarize a publication by Wessels, A.M. et al. (2021) in "Drug Discovery Today" discussing how researchers can use a combination of methods and tools to develop algorithms to make informed decisions about whether to continue or halt the development of a potential drug. 📈 From target engagement to digital biomarkers, click through to learn how to combine various methods to tailor your trial's Go/No-Go criteria.

In this webinar, Prof. Paul Maruff will provide a framework for understanding the nature and magnitude of cognitive impairment that can occur in disorders of the sleep/wake cycle. Register to learn how this framework can help your teams make informed decisions about the safety and efficacy of sleep-related drug candidates in drug development programs. 📅 Date: April 30th, 2024 🕒 Time: 11am ET ✅ Register here: https://lnkd.in/eAANmikY

The field of rare disease research recently celebrated the first FDA approval for the treatment of a rare genetic neurological disease, in this case for Rett Syndrome. Chief Science Officer, Pam Ventola, speaks about how an important part of this study design was the development of indication-specific outcome measures to better understand the significance of treatment effects in the target population. Watch the 2-min video here > https://lnkd.in/eDFjN5TN #RettSyndrome #RareDiseaseResearch #BrainHealthForAll

Cogstate Chief Innovation Officer, Prof Paul Maruff, shared data at the recent ADPD meeting showcasing the association between performance on Cogstate tests and biomarkers of Alzheimer’s disease. “These relationships were strong and statistically significant,” said Maruff. “They provide for us now a basis to start to understand the absolute genesis of Alzheimer’s disease, when it begins, and how it manifests.” 📊 View the poster here: https://lnkd.in/edYxJ7hN 🎥 Watch the poster video summary here: https://lnkd.in/ePtPQXjc

Congratulations to Stoke Therapeutics on its announcement of landmark data supporting STK-001 as a potential first disease-modifying medicine for individuals with Dravet Syndrome! Dravet syndrome is a severe and progressive genetic epilepsy that typically begins during the first year of life. Data from the Stoke Phase 1/2a study showed substantial and sustained reduction in convulsive seizure frequency in patients who were treated with STK-001. “This is a tremendous result for individuals who have Dravet Syndrome and their care givers,” said Pam Ventola, Cogstate CSO. “The frequency of seizures in Dravet Syndrome takes a cognitive, developmental, and physical toll on individuals and has a pronounced impact on the quality of life for the family, and any reduction is a huge advantage.” Read the full announcement here > https://lnkd.in/dG24yvQt

When clinical raters are part of a CNS clinical trial, it can be vital to the integrity of trial results that they collect and score interviews the same way and maintain high inter-rater reliability. Felice Ockun has 25 years experience in global CNS clinical trials. In this article, she shares expert insights on maintaining rater data integrity throughout your trial and identifies 4 ways to catch rater drift (click the image below to access.) #CNStrials #ClinicalResearch #DataQuality #RaterTraining #Cogstate